

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Liquid Crystals

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713926090>

### Synthesis and mesomorphic properties of cholesteryl *p*-2,2,3,3,4,4,5,5-octafluoropentoxybenzoate

Chuan Qin Corresponding author<sup>a</sup>; Guobing Rong<sup>a</sup>; Jianxun Wen<sup>a</sup>; Aniko Vajda<sup>b</sup>; Nandor Eber<sup>b</sup>

<sup>a</sup> Department of Chemistry, East China University of Science and Technology, Shanghai 200237, PR China <sup>b</sup> Research Institute for Solid State Physics and Optics of the Hungarian Academy of Sciences, H-1525 Budapest, P.O.B. 49, Hungary

Online publication date: 12 May 2010

**To cite this Article** Qin Corresponding author, Chuan , Rong, Guobing , Wen, Jianxun , Vajda, Aniko and Eber, Nandor(2004) 'Synthesis and mesomorphic properties of cholesteryl *p*-2,2,3,3,4,4,5,5-octafluoropentoxybenzoate', *Liquid Crystals*, 31: 12, 1677 – 1679

**To link to this Article:** DOI: 10.1080/02678290410001716006

**URL:** <http://dx.doi.org/10.1080/02678290410001716006>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

*Preliminary communication*

## Synthesis and mesomorphic properties of cholesteryl *p*-2,2,3,3,4,4,5,5-octafluoropentoxybenzoate

CHUAN QIN\*, GUOBING RONG, JIANXUN WEN

Department of Chemistry, East China University of Science and Technology,  
Shanghai 200237, PR China

ANIKO VAJDA and NANDOR EBER

Research Institute for Solid State Physics and Optics of the Hungarian Academy  
of Sciences, H-1525 Budapest, P.O.B. 49, Hungary

(Received 10 October 2003; in final form 20 February 2004; accepted 17 March 2004)

Cholesteryl *p*-2,2,3,3,4,4,5,5-octafluoropentoxybenzoate was synthesized and its phase transition behaviour studied by differential scanning calorimetry and thermal polarizing microscopy. The results show that the compound has SmA and monotropic SmE phases.

Ferroelectric liquid crystals (FLCs) have been intensively studied in recent years owing to their excellent memory effect and high response speed. These ferroelectric liquid crystalline compounds contain one or more chiral centres. The steroid group provides a cheap chiral resource: in 1992, Vill *et al.* reported that steroidal liquid crystals containing a long alkyl chain, e.g. cholesteryl *p*-hexadecylbenzoate and cholesteryl *p*-hexadecyloxyphenylcarbonate, display monotropic ferroelectric phases [1]. It is also known that liquid crystals containing highly fluorinated alkyl or alkoxy chains as terminal groups tend to form a smectic C phase with increasing temperature range [2–4]. Janulis *et al.* have shown the influence of  $(\text{CH}_2)_n$ , as a spacer between the fluorinated tail and the rigid core, on the nature of the mesomorphic phase is notable for producing a smectic C phase [5]. Therefore the homologous cholesteryl 4-polyfluoroalkoxy-3-nitrobenzoate **1** was synthesized by our group (figure 1) [6]. In order to study the effect of the lateral nitro group on mesophase formation, cholesteryl 2,2,3,3,4,4,5,5-*p*-octafluoropentoxybenzoate **2** was synthesized (figure 1 and the scheme). However, the desired SmC\* phase was not observed in these compounds. The SmE phase was found in compound **2**.

The mesophase behaviour of compound **2** was studied using polarizing optical microscopy (Amplival Pol U equipped with a Boetius hot stage). Differential scanning calorimetry was carried out with a Mettler

DSC FP80HT. The sample was incorporated into a 4.7  $\mu\text{m}$  thick, polyimide-coated ITO cell, purchased from Lincome Co. For electro-optical studies, a digital oscilloscope (DS 6612) and a function generator (Type TR-0463) were used. The results are summarized in the table.

From a comparison of the mesomorphic properties of compounds **1** and **2**, some interesting results have been obtained. Firstly, the clearing point was increased on eliminating the lateral nitro group, but the melting point was decreased. The mesomorphic range of non-nitro-substituted compound **2** becomes wider than that of the nitro derivative. Secondly, compound **2** shows no enantiotropic Ch phase but an enantiotropic SmA phase was observed. Nitro derivative **1** with  $n=4$  exhibits both an enantiotropic Ch phase and a monotropic SmA phase. Compound **1** with  $n=8$ , like compound **2**, shows no enantiotropic Ch phase but





Figure 1. The molecular structures of compounds **1** and **2**.

\*Author for correspondence; e-mail: qinchuan@ecnst.edu.cn



Scheme. The synthesis of cholesteryl 2,2,3,3,4,4,5,5-*p*-octafluoropentoxybenzoate **2**.

Table 1. The transition temperatures of the synthesized compounds. Cr = crystal; Ch = cholesteric phase; SmA = smectic A phase; I = isotropic phase; SmE = smectic E phase; Recr = recrystallization.

Compound	<i>n</i>	Transition temperatures/°C
<b>1</b>	2	Cr 179.0 Ch 183.8 I 179.9 Ch 121.9 Recr
	4	Cr 178.0 Ch 184.4 I 176.5 Ch 155.8 SmA137.3 Recr
	8	Cr 164.3 SmA 209.0 I 194.1 SmA 131.9 Recr
<b>2</b>	4	Cr 175.0 SmA 195-210 I 210-195 SmA 175 SmE 116 Recr

does exhibit an enantiotropic SmA phase. Thirdly, a highly ordered smectic SmE phase, which was not observed in the nitro derivative, was observed in the non-nitro compound **2** during cooling (figure 2). Thus the introduction of a long rigid fluorinated side chain and elimination of the nitro group suppress the cholesteric phase and increase the thermal stability and temperature range of the smectic phase. Eliminating the nitro group, although decreasing the molecular polarity, results in increased arrangement order, which favours the observed smectic ordering.




Figure 2. Optical polarizing micrograph of compound **2** smectic E phase (12.5 × 12.5).

This work was supported by the National Natural Science Foundation of China.

#### Appendix

Cholesteryl *p*-2,2,3,3,4,4,5,5-octafluoropentoxybenzoate **2** was synthesised according to the scheme. The structures of the final product and intermediates were elucidated by a variety of spectral methods. <sup>1</sup>H NMR spectra were recorded on a Bruker AM-500 spectrometer with TMS as internal standard. MS spectra were measured on a micromass GCT. IR spectra were recorded on a Nicolet FTIR 20sx spectrometer using solid KBr pellets.

The following are the results of identification analysis on the intermediate materials and the target compound cholesteryl *p*-octafluoropentoxybenzoate **2**.

*4*-(2,2,3,3,4,4,5,5)-Octafluoropentoxy-3-aminobenzoic acid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (ppm): 4.55 (t, 2H, *J* = 12.70 Hz, OCH<sub>2</sub>CF<sub>2</sub>), 6.08 (tt, 1H, *J*<sub>1</sub> = 46.63 Hz, *J*<sub>2</sub> = 5.30 Hz, HCF<sub>2</sub>), 6.82 (d, 1H, *J* = 8.49 Hz, ArH), 7.27 (s, 1H, ArH), 7.47 (d, 1H, *J* = 1.87 Hz, ArH), 7.53 (dd, 1H, *J*<sub>1</sub> = 6.57 Hz, *J*<sub>2</sub> = 1.90 Hz, ArH). MS (*m/z*, %): 367.2 (M<sup>+</sup>, 100.00), 350.2 (M<sup>+</sup> - OH, 2.55), 322.2 (M<sup>+</sup> - COOH, 1.23), 152.1 (M<sup>+</sup> - CH<sub>2</sub>CF<sub>2</sub>CF<sub>2</sub>CF<sub>2</sub>CF<sub>2</sub>H, 39.91).

*p*-2,2,3,3,4,4,5,5-Octafluoropentoxy benzoic acid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ (ppm): 4.54 (t, 2H, *J* = 12.84 Hz, OCH<sub>2</sub>CF<sub>2</sub>), 6.08 (tt, 1H, *J*<sub>1</sub> = 46.53 Hz, *J*<sub>2</sub> = 5.40 Hz, HCF<sub>2</sub>), 7.00 (dd, 2H, *J*<sub>1</sub> = 6.90 Hz, *J*<sub>2</sub> = 2.48 Hz, ArH), 8.12 (dd, 2H, *J*<sub>1</sub> = 5.31 Hz, *J*<sub>2</sub> = 2.78 Hz, ArH). MS (*m/z*, %): 352.0 (M<sup>+</sup>, 100.00), 335.0 (M<sup>+</sup> - OH, 29.54),

308.0 ( $M^+ - \text{COOH} + 1$ , 19.66), 151.0 ( $M^+ - \text{CF}_2\text{CF}_2 - \text{CF}_2\text{CF}_2\text{H}$ , 33.72).

*Cholesteryl p-2,2,3,3,4,4,5,5-octafluoropentoxybenzoate 2*.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  (ppm): 0.63 (s, 6H), 0.80–1.98 (m, 35H), 2.38 (d, 2H,  $J=7.78$  Hz), 4.45 (t, 2H,  $J=12.84$  Hz,  $\text{OCH}_2\text{CF}_2$ ), 4.77 (m, 1H), 5.53 (d, 1H,  $J=3.93$  Hz), 6.02 (tt, 1H,  $J_1=41.13$  Hz,  $J_2=5.40$  Hz,  $\text{HCF}_2$ ), 6.88 (d, 2H,  $J=8.88$  Hz, ArH), 7.97 (d, 2H,  $J=8.88$  Hz, ArH). MS ( $m/z$ , %): 720.3 ( $M^+$ , 0.19), 368.3 ( $\text{OCh}^+$ , 78.46), 350.2 ( $M^+ - \text{OCh}$ , 100). IR (KBr)  $\text{cm}^{-1}$ : 2950, 2850, 1712, 1614, 1520, 1472, 1370, 1320, 1280, 1250, 1170, 1120, 1080, 1050, 1000, 910, 870, 840, 800, 770, 750, 690, 630, 550.

### References

- [1] VILL, V., THIEM, J., and ROLLIN, P., 1992, *Z. Naturforsch.*, **47**, 515.
- [2] BLINOV, L.-M., KONONOV, S.-G., and TOURNILHAC, F., 1994, *Mol. Cryst. Liq. Cryst. Sci. Technol., C*, **3**, 229.
- [3] LAFFITTE, J. D., MAUZAC, M., TWIEG, R. J., NGUYEN, H.-T., and SIGAUD, G., 1994, *Liq. Cryst.*, **16**, 223.
- [4] NGUYEN, H.-T., SIGAUD, G., ACHARD, M.-F., HARDOUIN, F., TWIEG, R. J., and BETTERTON, K., 1991, *Liq. Cryst.*, **10**, 389.
- [5] JANULIS, E.-P., OSTEN, D.-W., RADCLIFFE, M.-D., NOVACK, J.-C., TRISTANI-KENDRA, M., EPSTEIN, K.-A., KEYES, M., JOHNSON, G.-C., SAVU, P.-M., and SPAWN, T.-D., 1992, *SPIE*, **1665**, 146.
- [6] WANG, K., LI, H. F., and WEN, J. X., 2001, *J. fluorine Chem.*, **109**, 205.